Currently there are no treatments capable of curing metastatic melanoma and resistance to most treatment options occurs within six months. The complete absence of the transcription factors MITF and BRN2 in a small subpopulation of tumour cells may contribute towards resistance to therapy. This project will investigate the importance of these two transcription factors for response to therapy.
To determine if dual loss of MITF and BRN2 is responsible for recurrent, therapy resistant, metastatic melanoma.
This project will require the generation of melanoma cell lines with the inducible removal of both MITF and BRN2. Two and three dimensional growth assays will be utilised to measure drug sensitivities. Animal experiments will be used to validate some results.
- Honours project only.